Pharmacogenetic (PGx) testing laboratories are tasked with quickly analyzing samples and reporting results. It can be a challenge to accurately characterize samples or even to generate results. Labs are often required to analyze challenging samples with low-quality DNA. Increased prevalence of self-collection exacerbates the issue as samples are collected at home or in an off-site location and mailed to the laboratory.
Additionally, it is estimated that up to 13% of the general population possesses a CYP2D6 hybrid allele. These unique rearrangements often go undetected when samples are characterized using common PGx testing methods. Hybrid alleles render the CYP2D6 gene non-functional. Not detecting them can lead to mischaracterization of drug metabolism status.
This webinar focuses on how PGx testing labs can respond to these common challenges and accurately characterize samples.
- Common PGx testing challenges including low-quality DNA and CYP2D6 hybrid alleles
- How common challenges lead to sample mischaracterization
- Testing methods to respond to these challenges and deliver accurate results
Robin Everts, PhD, Agena Bioscience Scientist
Recorded on June 25, 2019
Learn more about our pharmacogenetics solutions.